TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

ConferenceNeutral

AI Analysis

Summary

TuHURA Biosciences announced that its President and Chief will present at the H.C. Wainwright 28th Annual Global Investment Conference. The company is a Phase 3 immuno-oncology developer focused on overcoming resistance to cancer immunotherapy.

Clinical Trial Data

Phase

Phase 3

Importance:2/10

Sentiment:

0.00

immuno-oncologycancer immunotherapyconference presentationPhase 3

Related Companies

$HURA

Read the original article

Published by PR Newswire Biotech on September 8, 2026 11:45 AM

Read Original